64% of large firms say GLP-1 drug coverage moderately or significantly impacted their prescription drug spending Similar to the findings on use, 43% of firms with 1,000 to 4,999 workers, and 66% of firms with 5,000 or more workers, say that covering GLP-1 agonists for weight loss had a significant impact on the health plans prescription drug spending
FTC and DOJ Civil Lawsuit June 2024 On June 10, 2024, the Department of Justice and Federal Trade Commission filed an amended complaint seeking injunctive relief, damages, and penalties against Zealthy Inc., Gronk Inc., Bruno Health P.A., and various executives for allegedly unfair and deceptive privacy, data security, marketing, and billing practices
In some people, this GERD may trigger a change in the cells lining the lower esophagus, causing Barretts esophagus
That's a problem, since clinical data has shown that the majority of patients regain most of the weight they lost on a GLP-1 after they stop taking it